Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

	Related Links


	Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase IV Health services research, Treatment Active 18 and over Pharmaceutical / Industry 13102
NCT00771147

Trial Description

Summary

Evaluation of the efficacy and safety of Nexavar ® in advanced Renal Cell Carcinoma (RCC) and calculation of related medical costs.

Eligibility Criteria

Inclusion Criteria:

Patients with diagnosis of advanced RCC and decision taken by the investigator to prescribe Nexavar®. The patients should have sufficient knowledge of French or Dutch to be able to participate in the Study

Exclusion Criteria:

Exclusion criteria must be read in conjunction with the Belgian product information

Trial Contact Information

Trial Lead Organizations/Sponsors

Bayer Corporation

Bayer Study Director

Study Director

Bayer Clinical Trials Contact
		Email: clinical-trials-contact@bayerhealthcare.com

Trial Sites

Belgium

AALST

Study Site

ANTWERPEN

Study Site

ARLON

Study Site

BONHEIDEN

Study Site

BRASSCHAAT

Study Site

BRUGGE

Study Site

BRUXELLES - BRUSSEL

Study Site

DENDERMONDE

Study Site

GENT

Study Site

IEPER

Study Site

LA LOUVIERE

Study Site

LIEGE

Study Site

OOSTENDE

Study Site

ROESELARE

Study Site

TURNHOUT

Study Site

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00771147
Information obtained from ClinicalTrials.gov on April 06, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.